nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).

被引：6
|
作者：
Firdaus, Irfan
Waterhouse, David Michael
Gutierrez, Martin
Wainberg, Zev A.
George, Ben
Kelly, Karen
Bekaii-Saab, Tanios S.
Carrizosa, Daniel R.
Soliman, Hatem Hussein
Fraser, Cindy Duval
Ko, Amy
Pierce, Daniel W.
Manax, Victoria G.
Stergiopoulos, Sotirios G.
Hochster, Howard S.
机构：
[1] Oncol Hematol Care Inc, Sarah Cannon Res Inst, Cincinnati, OH USA
[2] OHC Oncol Hematol Care, Blue Ash, OH USA
[3] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[4] Ronald Regan UCLA Med Ctr, Los Angeles, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Levine Canc Inst, Charlotte, NC USA
[9] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[10] Celgene Corp, Summit, NJ USA
[11] Celgene Corp, Great Neck, NY USA
[12] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS475
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
    Hochster, Howard S.
    Wainberg, Zev A.
    Gutierrez, Martin
    Waterhouse, David
    Chiorean, E. Gabriela
    George, Ben
    Ko, Amy
    Manax, Victoria
    Stergiopoulos, Sotirios
    O'Dwyer, Peter
    CANCER RESEARCH, 2016, 76
  • [4] Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
    Ernani, Vinicius
    Akunyili, Ikechukwu Immanuel
    Hosein, Peter Joel
    Macintyre, Jessica
    Lima, Caio Max S. Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [5] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
    Wainberg, Zev A.
    Hochster, Howard S.
    George, Ben
    Gutierrez, Martin
    Johns, Mark Emery
    Chiorean, E. Gabriela
    Kwak, Eunice Lee
    Kalyan, Aparna
    Manax, Victoria
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Lowery, Maeve Aine
    Harding, James J.
    Yu, Kenneth H.
    Kelsen, David Paul
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [8] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345